The Rheumatologist’s Role in Sarcoidosis

Take-Home Points

In summary, sarcoidosis is a fascinating multi-system inflammatory disease that rheumatologists are uniquely positioned to treat. It’s time for us to step up to the plate and collaborate with our colleagues on multi-disciplinary teams to better care for these patients.

Samantha C. Shapiro, MD, is a clinician educator who is passionate about the care and education of rheumatology patients. She writes for both medical and lay audiences and practices telerheumatology.

References

1. Yee AMF. Sarcoidosis: Rheumatology perspective. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):334–356.
2. Fuss M, Pepersack T, Gillet C, et al. Calcium and vitamin D metabolism in granulomatous diseases. Clin Rheumatol. 1992 Mar;11(1):28–36.
3. Crouser ED, Maier LA, Baughman RP, et al. Diagnosis and detection of sarcoidosis an official American Thoracic Society Clinical Practice guideline. Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26–e51.
4. Baughman RP, Winget DB, Lower EE. Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis. 2000 Mar;17(1):60–66.
5. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial. Eur Respir J. 2008 Jun;31(6):1189–1196.
6. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med. 2006 Oct 1;174(7):795–802.
7. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003 Jul 1;107(25):3133–3140.
8. Baker MC, Sheth K, Witteles R, et al. TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Semin Arthritis Rheum. 2020 Jun;50(3):546–552.
9. Damsky W, Wang A, Kim DJ, et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat Commun. 2022 Jun 6;13(1):3140.
10. Yee AMF. Durable medication-free remission of sarcoidosis following discontinuation of anti-tumor necrosis factor-α therapy. Respir Med. 2023 Jan:206:107055.